Erich Mounce: Biosimilars and the OCM

Transcript

Absolutely. I think so. I think that community oncology needs to embrace biosimilars. I think we have to make sure everybody's on the same page with how you consent patients for biosimilars. I think you have to understand what a biosimilar is, and that also is difficult for some practices to understand the interchangeability of that, but I absolutely think they can hit the goals. I absolutely think that biosimilars are going to transform the way we can participate in value-based contracts, whether it's OCM or a value-based contract with a payer.